Literature DB >> 12446449

Splenic marginal zone lymphoma.

Vito Franco1, Ada Maria Florena, Emilio Iannitto.   

Abstract

Splenic marginal zone lymphoma (SMZL) is a specific low-grade small B-cell lymphoma that is incorporated in the World Health Organization classification. Characteristic features are splenomegaly, moderate lymphocytosis with villous morphology, intrasinusoidal pattern of involvement of various organs, especially bone marrow, and relative indolent course. Tumor progression with increase of blastic forms and aggressive behavior are observed in a minority of patients. Molecular and cytogenetic studies have shown heterogeneous results probably because of the lack of standardized diagnostic criteria. To date, no definitive therapy has been established. Therapeutic options include treatment abstention, splenectomy, splenic irradiation, and chemotherapy.

Entities:  

Mesh:

Year:  2002        PMID: 12446449     DOI: 10.1182/blood-2002-07-2216

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  32 in total

1.  Re: "Splenic marginal zone B-cell lymphoma associated with primary Sjögren's syndrome".

Authors:  Vito Franco; Emilio Iannitto; Claudio Tripodo; Ada Maria Florena
Journal:  Clin Rheumatol       Date:  2005-04       Impact factor: 2.980

2.  Primary splenic diffuse large B-cell lymphoma manifesting in red pulp.

Authors:  Makoto Kashimura; Masahiro Noro; Bunshiro Akikusa; Atsushi Okuhara; Shuji Momose; Ikuo Miura; Masaru Kojima; Jun-Ichi Tamaru
Journal:  Virchows Arch       Date:  2008-09-26       Impact factor: 4.064

3.  Splenectomy with chemotherapy vs surgery alone as initial treatment for splenic marginal zone lymphoma.

Authors:  Rajko Milosevic; Milena Todorovic; Bela Balint; Miodrag Jevtic; Miodrag Krstic; Elizabeta Ristanovic; Nebojsa Antonijevic; Mirjana Pavlovic; Maja Perunicic; Milan Petrovic; Biljana Mihaljevic
Journal:  World J Gastroenterol       Date:  2009-08-28       Impact factor: 5.742

4.  Splenic diffuse red pulp small B-cell lymphoma: revision of a series of cases reveals characteristic clinico-pathological features.

Authors:  George Kanellis; Manuela Mollejo; Santiago Montes-Moreno; Socorro-María Rodriguez-Pinilla; Juan C Cigudosa; Patricia Algara; Carlos Montalban; Estella Matutes; Andrew Wotherspoon; Miguel A Piris
Journal:  Haematologica       Date:  2010-03-10       Impact factor: 9.941

Review 5.  Optimal processing of bone marrow trephine biopsy: the Hammersmith Protocol.

Authors:  K N Naresh; I Lampert; R Hasserjian; D Lykidis; K Elderfield; D Horncastle; N Smith; W Murray-Brown; G W Stamp
Journal:  J Clin Pathol       Date:  2006-09       Impact factor: 3.411

6.  First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomas.

Authors:  Roberto Castelli; Luigi Bergamaschini; Giorgio Lambertenghi Deliliers
Journal:  Med Oncol       Date:  2017-12-29       Impact factor: 3.064

7.  Meningeal lymphomatosis as the first manifestation of splenic marginal zone lymphoma.

Authors:  Jordi Bruna; Sergio Martínez-Yelamos; Esther Alonso; Vicente Romagosa; Jordi Arruga; Jordi Arruga; Alicia Domingo; Iñigo Rojas-Marcos; Josep Petit; Francisco Rubio
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

8.  Marginal zone lymphoma: old, new, targeted, and epigenetic therapies.

Authors:  Monika Joshi; Hassan Sheikh; Kamal Abbi; Sarah Long; Kamal Sharma; Mark Tulchinsky; Elliot Epner
Journal:  Ther Adv Hematol       Date:  2012-10

9.  Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy.

Authors:  Christina Kalpadakis; Gerassimos A Pangalis; Maria K Angelopoulou; Sotirios Sachanas; Flora N Kontopidou; Xanthi Yiakoumis; Stella I Kokoris; Evagelia M Dimitriadou; Maria N Dimopoulou; Maria Moschogiannis; Penelope Korkolopoulou; Marie-Christine Kyrtsonis; Marina P Siakantaris; Theodora Papadaki; Panayiotis Tsaftaridis; Eleni Plata; Helen E Papadaki; Theodoros P Vassilakopoulos
Journal:  Oncologist       Date:  2013-01-23

10.  Osteosarcoma: mouse models, cell of origin and cancer stem cell.

Authors:  Maria V Guijarro
Journal:  Postdoc J       Date:  2014-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.